Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 20, 2010, Pages 6048-6051

  Staben, Steven T ^a   Heffron, Timothy P ^a   Sutherlin, Daniel P ^a   Bhat, Seema R ^a   Castanedo, Georgette M ^a   Chuckowree, Irina S ^b   Dotson, Jenna ^a   Folkes, Adrian J ^b   Friedman, Lori S ^a   Lee, Leslie ^a   Lesnick, John ^a   Lewis, Cristina ^a   Murray, Jeremy M ^a   Nonomiya, Jim ^a   Olivero, Alan G ^a   Plise, Emile ^a   Pang, Jodie ^b   Prior, Wei Wei ^a   Salphati, Laurent ^b   Rouge, Lionel ^a   Sampath, Deepak ^a   Tsui, Vickie ^a   Wan, Nan Chi ^b   Wang, Shumei ^a   Weismann, Christian ^a   Wu, Ping ^a   Zhu, Bing Yan ^a   more..

^a GENENTECH INC   (United States)

^b Medicinal Chemistry Department   (United Kingdom)

Author keywords

Oncology; PI3 kinase; Structure based drug design

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PYRAZOLOPYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG DESIGN; IN VIVO STUDY; MALE; MOLECULAR MODEL; NONHUMAN; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PROSTATE CANCER; RAT; STRUCTURE ANALYSIS; TUMOR XENOGRAFT; X RAY CRYSTALLOGRAPHY;

ANIMALS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HUMANS; MALE; MICE; MODELS, MOLECULAR; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; PYRIMIDINES; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77956924566     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.08.067     Document Type: Article

References (35)

1. L. Shayesteh, W.L. Kuo, R. Baldocchi, T. Godfrey, C. Collins, D. Pinkel, B. Powell, G.B. Mills, and J.W. Gray Nat. Genet. 21 1999 99
2. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, H. Yan, A. Gazdar, S.M. Powell, G.J. Riggins, J.K. Willson, S. Markowitz, K.W. Kinzler, B. Vogelstein, and V.E. Velculescu Science 30 2004 554
3. D.W. Parsons, T.L. Wang, Y. Samuels, A. Bardelli, J.M. Cummins, L. DeLong, N. Silliman, J. Ptak, S. Szabo, J.K. Willson, S. Markowitz, K.W. Kinzler, B. Vogelstein, C. Lengauer, and V.E. Velculescu Nature 436 2005 792
4. B.T. Hennessy, D.L. Smith, P.T. Ram, Y. Lu, and G.B. Mills Nat. Rev. Drug Disc. 4 2005 98
5. S. Wee, C. Lengauer, and D. Wiederschain Curr. Opin. Oncol. 20 2008 77
6. N. Chalhoub, and S.J. Baker Annu. Rev. Pathol. Mech. Dis. 4 2009 127
7. R. Marone, V. Cmiljanovic, B. Giese, and M.P. Wymann Biochim. Biophys. Acta 2008 159
8. T.A. Yap, M.D. Garrett, M.I. Walton, F. Raynaud, J.S. de Bono, and P. Workman Curr. Opin. Pharmacol. 8 2008 393
9. T. Crabbe, M.J. Welham, and S.G. Ward Trends Biochem. Sci. 32 2007 460
10. For select examples see: A.J. Folkes, K. Ahmadi, W.K. Alderton, S. Aliz, S.J. Baker, G. Box, I.S. Chuckowree, P.A. Clarke, P. Depledge, S.A. Eccles, L.S. Friedman, A. Hayes, T.C. Hancox, A. Kugendradas, L. Lensun, P. Moore, A.G. Olivero, J. Pang, S. Patel, G. Pergl-Wilson, F.I. Raynaud, A. Robson, N. Saghir, L. Salphati, S. Sohal, M.H. Ultsch, M. Valenti, H.J.A. Wallweber, N.C. Wan, C. Wiesmann, P. Workman, A. Zhyvoloup, M.J. Zvelebil, and S.J. Shuttleworth J. Med. Chem. 51 2008 5522
11. C.J. Vlahos, W.F. Matter, K.Y. Hui, and R.F. Brown J. Biol. Chem. 269 1994 5241
12. M. Hayakawa, H. Kaizawa, H. Moritomo, T. Koizumi, T. Ohishi, M. Yamano, M. Okada, M. Ohta, S.-I. Tsukamoto, F.I. Raynaud, P. Workman, M.D. Waterfield, and P. Parker Bioorg. Med. Chem. Lett. 17 2007 2438
13. M. Hayakawa, H. Kaizawa, H. Moritomo, T. Koizumi, T. Ohishi, M. Okada, M. Ohta, S.-I. Tsukamoto, P. Parker, P. Workman, and M. Waterfield Bioorg. Med. Chem. 14 2006 6847
14. A. Rikki, B. Ahrani, M. Batchelor, D. Brookings, K. Crepy, T. Crabbe, M.-F. Deltent, F. Driessens, A. Gill, S. Harris, G. Hutchinson, C. Kulisa, M. Merriman, P. Mistry, T. Parton, J. Turner, I. Whitcombe, and S. Wright Bioorg. Med. Chem. Lett. 18 2008 4316
15. C.M. Dehnhardt, A.M. Venkatesan, E. Delos Santos, Z. Chen, O. Santos, S. Ayral-Kaloustian, N. Brooijmns, R. Mallon, I. Hollander, L. Feldberg, J. Lucas, I. Chudhary, K. Yu, J. Gibbons, R. Abraham, and T.S. Mansour J. Med. Chem. 53 2010 798
16. A. Zask, J. Kaplan, J.C. Verheijen, D.J. Richard, K. Curran, N. Brooijmans, E.M. Bennett, L. Toral-Barza, I. Hollander, S. Ayral-Kaloustian, and K. Yu J. Med. Chem. 52 2009 7942
17. B. Perry, R. Alexander, G. Bennett, G. Buckley, T. Ceska, T. Crabbe, V. Dale, L. Gowers, H. Horsley, L. James, K. Jenkins, K. Crepy, C. Kulisa, H. Lightfoot, C. Lock, S. Mack, T. Morgan, A.-L. Nicolas, W. Pitt, V. Sabin, and S. Wright Bioorg. Med. Chem. Lett. 18 2008 4700
18. D.P. Sutherlin, D. Sampath, M. Berry, G. Castanedo, Z. Chang, I. Chuckowree, J. Dotson, A. Folkes, L. Friedman, R. Goldsmith, T. Heffron, L. Lee, J. Lesnick, C. Lewis, S. Mathieu, J. Nonomiya, A. Olivero, J. Pang, W.W. Prior, L. Salphati, S. Sideris, Q. Tian, V. Tsui, N.C. Wan, S. Wang, C. Wiesmann, S. Wong, and B.-Y. Zhu J. Med. Chem. 53 2010 1086
19. T.P. Heffron, M. Berry, G. Castanedo, C. Chang, I. Chuckowree, J. Dotson, A. Folkes, J. Gunzner, J.D. Lesnick, C. Lewis, S. Mathieu, J. Nonomiya, A. Olivero, J. Pang, D. Peterson, L. Salphati, D. Sampath, S. Sideris, D.P. Sutherlin, V. Tsui, N.C. Wan, S.M. Wang, S. Wong, and B.Y. Zhu Bioorg. Med. Chem. Lett. 20 2010 2408
20. X-ray structures of 6 and 1d have been deposited in the PDB (id: 3NZS and 3NZU).
21. Lys833 is not well defined in the crystal structure density. This interaction could be more important in PI3Kα.
22. No detectable concentration after oral dosing at 5 mg/kg in 80% PEG/EtOH vehicle.
23. TPSA (topological polar surface area) calculation similar to that as described in: P. Ertl, B. Rohde, and P. Selzer J. Med. Chem. 43 2000 3714
24. H. Kwon, R.A. Lionberger, and L.X. Yu Mol. Pharm. 1 2004 455
25. J. Lin, M. Chiba, and T. Baillie Pharmacol. Rev. 1 1999 135
26. A. Collett, J. Tanianis-Hughes, D. Hallifax, and G. Warhurst Pharm. Res. 21 2004 819
27. Consistent with this statement, co-administration of Gefitinib (a known PgP and BCRP inhibitor) with compound 9 did result in improved bioavailablity of 9.
28. -6 cm/s, B-A/A-B = 17.60 for 9 in cell line C (Bcrp1-MDCKII) in the presence of Fumitremorgin C.
29. For examples, see L.R. Roberts, J. Bryans, K. Conlon, G. McMurray, A. Stobie, and G.A. Whitlock Bioorg. Med. Chem. Lett. 18 2008 6437
30. T.J. Raub Mol. Pharm. 3 2005 3
31. Study performed at Invitrogen; most significant was 27% inhibition of FLT 3.
32. The attenuated pathway knockdown for 12 can be attributed to its modest cellular pAKT activity as well as low exposure of free drug in this experiment (mouse plasma protein binding = 98.8%). Compound 12 was not tested in a mouse xenograft model for tumor growth inhibition. Determination of a MTD was not attempted.
33. For experimental data and characterization see: Dotson, J.; Heffron, T.; Olivero, A. O.; Sutherlin, D. P.; Staben, S. T.; Wang, S.; Zhu, B-Y.; Chuckowree, I. S.; Folkes, A. J.; Wan, N. C. WO/2010/059788; PCT/US2009/065085.
34. Dotson, J.; Heffron, T.; Olivero, A. O.; Sutherlin, D. P.; Wang, S.; Zhu, B-Y.; Chuckowree, I. S. Folkes, A. J.; Wan, N. C. WO/2009/097446; PCT/US2009/032459.
35. R. Ferroni, D. Simoni, P. Orlandini, A. Bardi, G.P. Franze, and M. Guarneri Arzneimittelforschung 40 1990 1328